
    
      Patients who meet the inclusion criteria (having a direct bilirubin ≥4.0 mg/dL) and are
      consented will be discontinued from standard soybean-based lipid emulsion and started on
      Omegaven®. Omegaven® will be infused continuously via either a peripheral or central catheter
      at a dose of 1 gm/kg/day along with parenteral nutrition (PN).
    
  